NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.00 Consensus Target Price from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $15.00.

A number of equities research analysts have commented on NPCE shares. Wells Fargo & Company reduced their target price on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th.

Insider Activity

In other news, major shareholder Ltd. Kck sold 223,991 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares of the company’s stock, valued at approximately $28,726,105.25. This represents a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.20% of the company’s stock.

Hedge Funds Weigh In On NeuroPace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares in the last quarter. Rhumbline Advisers purchased a new stake in NeuroPace during the 2nd quarter worth about $111,000. Financial Advocates Investment Management raised its position in NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares in the last quarter. Barclays PLC boosted its stake in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the period. Finally, XTX Topco Ltd grew its position in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Price Performance

NeuroPace stock opened at $11.97 on Tuesday. The company has a fifty day simple moving average of $10.92 and a 200-day simple moving average of $8.44. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The firm has a market capitalization of $357.30 million, a price-to-earnings ratio of -11.97 and a beta of 2.02. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter last year, the firm earned ($0.28) earnings per share. On average, equities analysts anticipate that NeuroPace will post -1 EPS for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.